H G Dörr1, G Binder2, N Reisch3, U Gembruch4, P G Oppelt5, P Wieacker6, J Kratzsch7. 1. Kinder- und Jugendklinik des Universitätsklinikums Erlangen, Erlangen. 2. Univ.-Kinderklinik Tübingen, Sektion Endokrinologie, Tübingen. 3. Medizinische Klinik und Poliklinik IV. Klinikum der Universität München, München. 4. Abteilung für Geburtshilfe und Pränatalmedizin der Universität Bonn, Bonn. 5. Kinder- und Jugendgynäkologie, Frauenklinik des Universitätsklinikums Erlangen, Erlangen. 6. Institut für Humangenetik, Universitätsklinikum Münster, Münster. 7. Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik der Universität Leipzig, Leipzig.
Abstract
Purpose: This guideline of the German Society of Pediatric Endocrinology and Diabetology (DGKED) is designed to be experts' opinion on the current concept of prenatal therapy for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). Several scientific medical societies have also participated in the guideline. It aims to offer guidance to physicians when they counsel affected families about prenatal therapy. Methods: The experts commissioned by the medical societies developed a consensus in an informal process. The consensus was subsequently confirmed by the steering committees of the respective medical societies. Recommendations: Prenatal CAH therapy is an experimental therapy. We recommend designing and using standardized protocols for the prenatal diagnosis, therapy and long-term follow-up of women and children treated prenatally with dexamethasone. If long-term follow-up is not possible, then prenatal therapy should not be performed.
Purpose: This guideline of the German Society of Pediatric Endocrinology and Diabetology (DGKED) is designed to be experts' opinion on the current concept of prenatal therapy for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). Several scientific medical societies have also participated in the guideline. It aims to offer guidance to physicians when they counsel affected families about prenatal therapy. Methods: The experts commissioned by the medical societies developed a consensus in an informal process. The consensus was subsequently confirmed by the steering committees of the respective medical societies. Recommendations: Prenatal CAH therapy is an experimental therapy. We recommend designing and using standardized protocols for the prenatal diagnosis, therapy and long-term follow-up of women and children treated prenatally with dexamethasone. If long-term follow-up is not possible, then prenatal therapy should not be performed.
Authors: Annick de Vries; Megan C Holmes; Areke Heijnis; Jürgen V Seier; Joritha Heerden; Johan Louw; Sonia Wolfe-Coote; Michael J Meaney; Naomi S Levitt; Jonathan R Seckl Journal: J Clin Invest Date: 2007-03-22 Impact factor: 14.808
Authors: Heino F L Meyer-Bahlburg; Curtis Dolezal; Rita Haggerty; Michael Silverman; Maria I New Journal: Eur J Endocrinol Date: 2012-05-01 Impact factor: 6.664
Authors: Bettina Toth; Dunja Maria Baston-Büst; Hermann M Behre; Alexandra Bielfeld; Michael Bohlmann; Kai Bühling; Ralf Dittrich; Maren Goeckenjan; Katharina Hancke; Sabine Kliesch; Frank-Michael Köhn; Jan Krüssel; Ruben Kuon; Jana Liebenthron; Frank Nawroth; Verena Nordhoff; Germar-Michael Pinggera; Nina Rogenhofer; Sabine Rudnik-Schöneborn; Hans-Christian Schuppe; Andreas Schüring; Vanadin Seifert-Klauss; Thomas Strowitzki; Frank Tüttelmann; Kilian Vomstein; Ludwig Wildt; Tewes Wischmann; Dorothea Wunder; Johannes Zschocke Journal: Geburtshilfe Frauenheilkd Date: 2019-12-11 Impact factor: 2.915
Authors: Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958